Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses.

ABSTRACT: Antimicrobial resistance continues to evolve and remains a leading cause of death worldwide, with children younger than 5 years being among those at the highest risk. Addressing antimicrobial resistance requires a comprehensive response, including infection prevention efforts, surveillance, stewardship, therapy appropriateness and access, and research and development. However, antimicrobial research and development is limited and lags behind the output of other fields, such as that of cancer or HIV research. The 2023 WHO analysis of the global antibacterial clinical pipeline serves as a tool to monitor and guide research and development efforts. The analysis emphasises the remaining gaps in developing a robust and effective antibacterial drug pipeline, drawing insights from trend analyses

SUBMITTER: Melchiorri D 

PROVIDER: S-EPMC11876093 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature